老年早期腔面型乳腺癌患者的化疗与基因表达谱检测:国际老年肿瘤学会系统综述
该系统综述检索 PubMed 和 Embase,评估化疗在老年激素受体阳性、HER2 阴性早期乳腺癌中的疗效、安全性及生活质量影响,并评估基因表达谱检测的使用与作用;共纳入 8 篇化疗相关文献(含 2035 例老年患者)和 5 篇基因表达谱文献(含 445323 例老年患者)。
要点
- 仅一项试验评估化疗对老年患者的生存获益,结果显示无获益。
- 基因表达谱检测在老年患者中使用较少,其预测作用尚未明确。
- 复发评分较高对远处复发有预后价值,但化疗未改善预后。
核心结论
- 在激素受体阳性、HER2 阴性早期乳腺癌老年患者中,化疗的生存获益尚不明确,基因表达谱检测使用较少;其预后作用已明确,但预测作用仍未知。
研究设计与样本
- 国际老年肿瘤学会系统综述,检索 PubMed 和 Embase 中评估老年激素受体阳性、HER2 阴性早期乳腺癌患者化疗的前瞻性研究,以及评估基因表达谱检测的回顾性和前瞻性研究。
主要发现
- 共纳入 8 篇化疗相关文献,包含 2035 例老年早期乳腺癌患者;仅一项试验评估化疗生存获益,显示无获益。
- 四项比较不同方案的研究中,仅一项显示紫杉类优于单用蒽环类;探索替代方案的研究未显示优于标准方案,但存在显著局限性。
- 共纳入 5 篇基因表达谱文献,包含 445323 例老年患者,均研究 Oncotype DX;有限证据显示基因表达谱有助于该人群的治疗决策。
- 与年轻患者相比,老年患者接受基因表达谱检测的频率更低;复发评分较高对远处复发有预后价值,但化疗未改善预后。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The benefit of chemotherapy for older patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (EBC) is a key area of debate. Gene expression profiling (GEP) may identify patients deriving benefit, but their predictive role has not been established for older adults. We summarise evidence on efficacy, safety, and quality-of-life impacts of chemotherapy and on GEP use and impact in older HR-positive, HER2-negative EBC patients. METHODS: We conducted a literature search of PubMed and Embase on publications describing prospective studies evaluating chemotherapy in older adults with HR-positive, HER2-negative EBC and on publications describing retrospective and prospective studies evaluating GEP in older adults. RESULTS: Eight publications on chemotherapy use, including 2,035 older patients with EBC were selected. Only one trial evaluated chemotherapy survival benefits in older adults, showing no benefit. Of four studies comparing different regimens, only one showed the superiority of taxanes versus anthracyclines alone. Those investigating alternative regimens did not show improvements over standard regimens despite significant limitations. Five publications on GEP, including 445,323 older patients, were included and investigated Oncotype DX. Limited evidence shows that GEP aids treatment decisions in this population. GEP was offered less frequently to older versus younger patients. Higher Recurrence Score was prognostic for distant recurrence, but chemotherapy did not improve prognosis. CONCLUSIONS: In older patients with HR-positive, HER2-negative, chemotherapy survival benefits EBC are unclear and GEP is less used. Although its prognostic role is well established, its predictive role remains unknown.
引用
- Battisti NML, De Glas N, Soto-Perez-de-Celis E, et al. Chemotherapy and gene expression profiling in older early luminal breast cancer patients: An International Society of Geriatric Oncology systematic review. Eur J Cancer. 2022. PMID: 35777273. doi:10.1016/j.ejca.2022.05.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。